Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001

What does the research say about Lactobacillus rhamnosus HN001?

3 health outcomes synthesised

Lactobacillus rhamnosus HN001 is a probiotic strain studied primarily for its effects on maternal and infant health, with research covering three health outcomes. The strongest evidence is for reducing anxiety in pregnant and postpartum women, supported by 4 studies showing moderate evidence strength at doses typically administered from pregnancy through breastfeeding. Effects on eczema and atopic sensitization in children show lower evidence strength, with mixed or neutral results.

Strongest evidence: The most robust research on Lactobacillus rhamnosus HN001 focuses on reduced anxiety in pregnant and postpartum women, with moderate evidence strength from 4 studies (3 beneficial, 1 neutral). A large randomized controlled trial in 423 women found a significant reduction in clinically relevant anxiety (OR=0.44). Effect sizes range from small to moderate. The effective dose varied: one study used daily supplementation from enrolment until 6 months postpartum if breastfeeding, another from 35 weeks gestation through six months of breastfeeding.

Mixed or weaker evidence: For reduced eczema prevalence, evidence is low (3 RCTs, only 1 beneficial, 2 neutral) and conclusions are preliminary. The one positive trial supplemented both mothers and infants from late pregnancy through age 2, whereas maternal-only supplementation showed no effect, suggesting timing and duration matter. For reduced prevalence of atopic sensitization, all 3 studies found neutral small effects with no statistical significance, yielding low evidence strength.

Effective dose patterns: Across outcomes, a common studied dose is 6 × 10^9 CFU daily, used in trials for eczema and atopic sensitization. For anxiety, dosing schedules varied around pregnancy and breastfeeding periods rather than a fixed CFU number. No consistent dose range applies across all three outcomes.

Population insights: The research predominantly involves pregnant women, postpartum women, and their infants, often in high-risk birth cohorts (e.g., family history of allergy). Benefit for anxiety appears specific to adult women in the perinatal period; one neutral study in children found no significant effect, suggesting population specificity.

Notable caveats: All three evidence bases are small (3–4 studies), so conclusions are preliminary. Publication bias may inflate positive results, especially for anxiety. For eczema, benefit may depend on dual mother-infant supplementation over a prolonged period. For atopic sensitization, the data consistently show no effect.

Frequently asked

  • What is Lactobacillus rhamnosus HN001 good for according to research?
    Research primarily supports its use for reducing anxiety in pregnant and postpartum women, with moderate evidence from 4 studies. Evidence for reducing eczema prevalence is mixed (low strength, 3 RCTs with only 1 positive), and evidence for reducing atopic sensitization is consistently neutral across 3 studies.
  • What dose of Lactobacillus rhamnosus HN001 is typically used in studies?
    The most common dose studied is 6 × 10^9 CFU daily, used in trials for eczema and atopic sensitization. For anxiety, dosing schedules varied — typically starting during pregnancy (from enrolment or 35 weeks gestation) and continuing through six months postpartum if breastfeeding.
  • Who benefits most from Lactobacillus rhamnosus HN001?
    Benefits are most consistently observed in pregnant and postpartum women for anxiety reduction. For eczema, one study suggested benefit when both mothers and infants were supplemented from late pregnancy through age 2. A study in children alone found no significant effect on anxiety, indicating population specificity.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus HN001?
    Yes. The evidence base is small for all outcomes (3–4 studies), making conclusions preliminary. Publication bias may overestimate benefits, particularly for anxiety. For eczema, only one trial showed a positive effect, and it required dual mother-infant supplementation; maternal-only supplementation showed no effect.
  • Does Lactobacillus rhamnosus HN001 help with eczema?
    Evidence is mixed and low strength. Of 3 randomized controlled trials, only 1 reported a large beneficial effect, while 2 found neutral small effects. Preliminary data suggest timing and duration may be critical — the positive trial supplemented both mothers and infants from late pregnancy through age 2 years.
  • Does Lactobacillus rhamnosus HN001 reduce allergies or atopic sensitization?
    Based on 3 randomized controlled trials, all reported neutral small effects with no statistically significant findings for reducing atopic sensitization. The evidence is low strength and does not support a benefit for this outcome.

Most-studied combinations with Lactobacillus rhamnosus HN001

most supplement research is combination research
Also studied with:Bifidobacterium lactis HN019 (3), Lactobacillus rhamnosus MAK79L08R (2), Bifidobacterium longum BB536 (2), Bifidobacterium animalis subsp. lactis HN019 (2)
Back to top